Immunic is trading at $16.75, up +5.15%, after investors continued responding to its August 11, 2026, Q2 results and smaller-than-expected loss per share.

  • Q2 loss per share was $0.80 versus an expected $1.18 loss.
  • ENSURE Phase 3 year-end 2026 data guidance remains on track; $155.1 million in cash funds operations into late 2027.
  • Broader risk-on sentiment, including stronger technology indexes, is supportive; the Nasdaq is up 0.80%.